J. Leonard Lichtenfeld, MD, Acting Chief Medical and Scientific Officer, American Cancer...
- ASCO 2019: Ribociclib Claims First Ever Overall Survival Benefit for Targeted Therapy. MONALEESA 7 confirms CDK4/6 inhibitor efficacy in younger women
- ASCO 2019: FDA Launches Project Facilitate to Ease Access to Novel Agents
- ASCO 2019: Getting on the Same Page with mCODE. ASCO unveils initiative to topple EHR ‘Tower of Babel’